Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Lutfi Alfarsi"'
Autor:
Walaa Mohammedsaeed, Fahad Alsehli, Lutfi Alfarsi, Ameen Bakhsh, Mansour Alzahrani, Maram Almarwani, Yousef Alharbi
Publikováno v:
Cureus.
Publikováno v:
Breast Cancer (Tokyo, Japan)
Purpose There are numerous biomarkers which may have potential predictive and prognostic significance in breast cancer. This is extremely important in older adults, who may opt for less aggressive therapy. This work outlines the literature on biologi
Autor:
Brendah K. Masisi, Lutfi Alfarsi, Emad A. Rakha, Madeleine L. Craze, Ian O. Ellis, Rokaya El Ansari, Andrew R. Green
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Cancer
BMC Cancer
Background PPFIA1 is an important regulator of cell migration and invasion, regulating focal adhesion signalling and disassembly. PPFIA1 is frequently amplified in breast cancer, and recent functional studies indicate that PPFIA1 is an important prom
Autor:
Lutfi Alfarsi, Ian O. Ellis, Maryam Althobiti, Emad A. Rakha, Andrew R. Green, Rokaya El Ansari, Madeleine L. Craze
Publikováno v:
British Journal of Cancer
Background Cancer cells must alter their metabolism to support proliferation. Immune evasion also plays a role in supporting tumour progression. This study aimed to find whether enhanced glutamine uptake in breast cancer (BC) can derive the existence
Autor:
Emad A. Rakha, Madeleine L. Craze, Lutfi Alfarsi, Brendah K. Masisi, Maria Diez-Rodriguez, Mohammed A. Aleskandarany, Andrew R. Green, Rokaya El-Ansari, Ian O. Ellis, Kiu Wai Cheng, Christopher C. Nolan
Publikováno v:
Breast Cancer Research and Treatment. 174:79-91
Dysregulated cellular metabolism is one of the hallmarks of cancer with some tumours utilising the glutamine metabolism pathway for their sustained proliferation and survival. Glutamate dehydrogenase (GLUD1) is a key enzyme in glutaminolysis converti
Autor:
Emad A. Rakha, Andrew R. Green, Lutfi Alfarsi, Ian O. Ellis, Madeleine L. Craze, Omar J. Mohammed, Rokaya El Ansari, Brendah K. Masisi
Publikováno v:
Breast Cancer Research and Treatment
Purpose Identification of effective biomarkers for the benefit of endocrine treatment and understanding the molecular pathways that contribute to the development of resistance are of crucial importance to the management of luminal breast cancer. The
Autor:
Lutfi Alfarsi, Emad A. Rakha, Ian O. Ellis, Omar J. Mohammed, Brendah K. Masisi, Ruth M. Parks, Andrew R. Green, Rokaya El Ansari
Publikováno v:
Cancers
Volume 12
Issue 6
Cancers, Vol 12, Iss 1549, p 1549 (2020)
Volume 12
Issue 6
Cancers, Vol 12, Iss 1549, p 1549 (2020)
Endocrine therapy is the mainstay of adjuvant treatment for patients with luminal breast cancer. Despite ongoing advances in endocrine therapy to date, a proportion of patients ultimately develop endocrine resistance, resulting in failure of therapy
Autor:
Madeleine L. Craze, Brendah K. Masisi, Lutfi Alfarsi, Rokaya El-Ansari, Ian O. Ellis, Emad A. Rakha, Omar J. Mohammed, Andrew R. Green
Publikováno v:
International Journal of Molecular Sciences
Volume 21
Issue 4
International Journal of Molecular Sciences, Vol 21, Iss 4, p 1407 (2020)
Volume 21
Issue 4
International Journal of Molecular Sciences, Vol 21, Iss 4, p 1407 (2020)
The majority of breast cancers are oestrogen-receptor-positive (ER+) and are subject to endocrine therapy
however, an unpredictable subgroup of patients will develop resistance to endocrine therapy. The SLC7A5/SLC3A2 complex is a major route for
however, an unpredictable subgroup of patients will develop resistance to endocrine therapy. The SLC7A5/SLC3A2 complex is a major route for
Publikováno v:
Histopathology. 73:545-558
Endocrine therapy for oestrogen receptor-positive (ER+) breast cancer (BC) is arguably the most successful targeted cancer therapy to date. Nevertheless, resistance to endocrine therapy still occurs in a significant proportion of patients, limiting i
Autor:
Andrew R. Green, Lutfi Alfarsi, Madeleine L. Craze, Brendah K. Masisi, Emad A. Rakha, Rokaya El Ansari, Ian O. Ellis
Publikováno v:
Breast Cancer Research and Treatment
Purpose Breast cancer (BC) is a heterogeneous disease consisting of various subtypes, with different prognostic and therapeutic outcomes. The amino acid transporter, SLC7A8, is overexpressed in oestrogen receptor-positive BC. However, the consequence